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Background: A recent study by the International Study of Asthma
and Allergies in Childhood has shown that asthma symptom pre-
valence is still increasing in parts of Asia. As such, it is important
to know how well asthma is being managed. Practices of physicians
in India, China, Sri Lanka, Australia, Singapore, Indonesia, Phil-
ippines, and Taiwan in monitoring and treating childhood asthma
were examined.
Methods: A 6-page standardized questionnaire was sent to physi-
cians via post. The questionnaire is made up of 3 parts, including
(1) methods of monitoring of childhood asthma, (2) practices in
managing acute asthma exacerbations, and (3) choice of therapy in
maintenance treatment.
Results: Our study reﬂects mostly the practices of physicians who
practice in urban regions. Of respondents, 41.4% were general pe-
diatricians, whereas 26.3% were general practitioners. A small frac-
tion of physicians used score cards or diaries to monitor asthma,
ranging from 0% (Philippines and Australia) to 15.9% (India). Only
8.1% (Sri Lanka) to 52.0% (Australia) use either a peak ﬂow meter
and/or spirometry to monitor asthma. However, for frequency of use,
35% (China) to 94% (Indonesia) never or seldom make use of a
peak ﬂow meter, and 33% (China) to 97.6% (Indonesia) never or
seldom use spirometry for monitoring. Most physicians treat acute
asthma appropriately with short-acting bronchodilators. For main-
tenance treatment, an inhaled corticosteroid was the most frequently
chosen ﬁrst-choice therapy. However, a signiﬁcant fraction of
physicians chose a long-acting A-agonist monotherapy as a ﬁrst-
choice treatment for asthma maintenance. For infants, the percentage
ranged from 1.4% (Australia) to 76.3% (Indonesia); in preschoolers,
1.8% (Australia) to 43.3% (Indonesia); and in older children, 0%
(Philippines) to 28.8% (Indonesia). These results may be related to
the overall afﬂuence of each nation.
Conclusions: There is much room for improvement in increasing
physicians’ awareness to guidelines for more effective management
of pediatric asthma in Southeast Asia, especially regarding the high
use of long-acting A-agonist monotherapy, even in young children.
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(WAO Journal 2009; 2:3Y8)
A recent report of a worldwide collaborative survey ofasthma and allergic diseases in children (International
Study of Asthma and Allergies in Childhood) has shown
that asthma symptom prevalence is still increasing in parts
of Asia.1 Asthma has been shown to start early in life. In
Singapore, 11.7% of preschoolers aged 4 to 6 years have
already been diagnosed with asthma.2 In fact, 60% of chil-
dren with asthma develop their symptoms before the age
of 3 years.3 In a cross-sectional study done in Singapore,
22.9% of children in their second year of age already had
the asthma-related symptom of wheezing.4 This indicates
that there is a need for asthma intervention in early years,
thus highlighting the importance of good asthma manage-
ment in children. There is also evidence to suggest that
severity of asthma in Asia is worsening. Increasing asthma
admission rates in Thailand have been reported, demonstrat-
ing a worsening in asthma severity in Thailand during the
last decade.5 As such, our aim was to examine practices of
physicians in Southeast Asia in treating childhood asthma.
MATERIALS AND METHODS
The study was performed using a standardized ques-
tionnaire that was distributed among randomly selected
groups of physicians. The questionnaire comprises 6 pages
and 29 items on (1) demographic data of the participant;
(2) monitoring of childhood asthma; (3) treating an acute
asthma attack in children; and (4) maintenance treatment of
childhood asthma in infants, preschoolers, and older chil-
dren. The main points of the questionnaire are summarized in
Table 1. Most of the countries studied had had the ques-
tionnaire distributed via post. Distribution of the question-
naires was mostly around urban regions.
The areas studied were Padang and Jakarta (Indonesia),
Perth (Australia), New Delhi (India), 25 cities in China, Met-
ro Manila (Philippines), and the whole countries of Taiwan,
Singapore, and Sri Lanka.
Responses were collected via reply e-mails within a
set 3-month period for reply and were then tabulated by 2
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investigators with cross-checking of results. This was sub-
sequently analyzed with SPSS Version 13.0. Descriptive
statistics were generated, and various cross tabulations and
tables were produced as a result.
RESULTS
Demographic Data
In total, 1905 respondents were surveyed from the
8 countries in Southeast Asia (Table 2). Response rates varied
from 8.3% in Singapore to 34.6% in Taiwan, although sig-
niﬁcantly higher response rates of 65% and 79.9% were
observed in the Philippines and Indonesia, respectively. Fifty-
ﬁve percent of the respondents were females, and 45% were
males. Ages of most responders ranged between 31 and 45
years, the percentage being 55. A large group of the res-
pondents were general pediatricians (41.4%), followed by
general practitioners, making up the next 26.3%.
Monitoring Childhood Asthma
Trends for this category were relatively similar for
all the countries. Only a small fraction of physicians used
score cards or diaries to monitor asthma, ranging from
0% (Philippines and Australia) to 15.9% (India). Generally,
a slightly higher percentage of physicians monitor pediat-
ric asthma using both peak ﬂow meters and spirometry, as
compared with only with peak ﬂow meters. A small minority
only use spirometry for monitoring of asthma (Table 3).
The frequency of monitoring of asthma using peak
ﬂow and spirometry was noted to be exceedingly low, as a
large percentage of physicians indicated that they seldom
or never use spirometry and peak ﬂow for monitoring.
Treating Acute Asthma Attacks in Children
Nebulized salbutamol given every 20 minutes was gen-
erally favored as the treatment of choice in treating acute
asthma attacks by most physicians in each country (Table 4).
In China, an additional 22% stated that they would opt for
temporarily administering inhaled salbutamol or terbutaline
and adopting a Bwait-and-see[ approach. Between one quar-
ter and two thirds of physicians frequently or always ad-
minister systemic corticosteroids in an outpatient setting
(emergency department or polyclinic) in the treatment of acute
asthma, whereas the overwhelming majority would use cor-
ticosteroids in the inpatient setting. The duration of choice was
generally cited to be 3 to 5 days. Physicians were mixed in
their use of antibiotics, and few physicians favored high-
dose inhaled corticosteroids in acute management. Majority
of over 80% per country never or seldom used aminophyl-
line as a ﬁrst-line treatment of asthma.
Maintenance Treatment of Childhood Asthma
in Children
Severity and frequency of the symptoms were the 2
main criteria physicians used to determine whether to start a
maintenance treatment in children with asthma. This ranged
from 19.5% (India) to 46.9% (Sri Lanka) for severity and
36% (China) to 73.1% (India) for frequency.
A signiﬁcant fraction of physicians chose long-acting A-
agonist (LABA) monotherapy as ﬁrst-choice treatment for
asthma maintenance (Table 5). Inhaled corticosteroid ther-
apy was selected as a ﬁrst-choice therapy for asthma main-
tenance in infants by 11.0% (Indonesia) to 81.6% (Sri Lanka)
of physicians. In preschoolers, it ranged from 10.0% (Indo-
nesia) to 69.4% (Sri Lanka) of physicians, and in older chil-
dren, it ranged from 24.0% (Indonesia) to 69.4% (Sri Lanka)
(Table 6).
Montelukast use as a ﬁrst-choice treatment was fa-
vored by 0.0% (Sri Lanka, Philippines) to 42.4% (Taiwan)
of respondents in infants. For preschoolers, the range was
from 1.9% (Indonesia) to 45.3% (Taiwan) of respondents, and
in older children, it ranged from 0.0% (India, Sri Lanka) to
19.8% (Taiwan) and 72% (China) (Tables 6 and 7).
DISCUSSION
There are little data on practices of asthma manage-
ment in Southeast Asia, although this has been widely stud-
ied in developing and developed parts of western countries.6Y8
Judging from the recent trend of increasing pediatric asth-
ma cases in this region,1 and as the economic cost of asthma
has been found to be considerable in populations outside the
western hemisphere (this has been found to be approximately
US $238 per asthmatic person per year in Singapore),9 it is
TABLE 2. Number of Respondents Per Country
India Australia Sri Lanka Taiwan China Indonesia Singapore Philippines
No. respondents 82 232 49 101 912 215 173 143
TABLE 1. Questionnaire Details
Section Subheading Questions
A Demographic data Sex, age, speciality, employment
B Monitoring childhood
asthma
Symptom score cards/diary cards/
peak flow meter/spirometry use
C Treating an acute asthma
attack in children
Drug of choice, criteria for
admission, use of bronchodilators,





Drug of choice, frequency of use of
maintenance treatment, criteria to
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TABLE 3. Percentages of Respondents Who Monitor Asthma With Peak Flow Meters or Spirometry
India Australia Sri Lanka Taiwan China Indonesia Singapore Philippines
Percentage of respondents who always monitor asthma with the following
Both peak flow and spirometry 29.3 44.2 2 25.7 29 6.5 7.5 8.4
Peak flow only 15.8 5.2 6.1 5 8 0.5 8.1 0
Spirometry only 0 2.6 0 0 5 0 0.6 0
Percentage of respondents who seldom or never monitor asthma with the following
Peak flow meter 43.8 47.4 75.5 45.6 35 94 47.6 69.9
Spirometry 81.6 64.5 100 85.2 33 97.6 55.6 95.8
TABLE 4. Treatment of Acute Attacks
India Australia Sri Lanka Taiwan China Indonesia Singapore Philippines
Salbutamol* 68.2 41.2 85.7 51.5 29 54.9 60.7 66.4
Systemic corticosteroids** 52.4 50.3 51.0 68.3 50 30.7 41.0 27.3
Inhaled corticosteroids‡ 48.7 49.4 26.5 39.6 82 47.9 60.1 54.6
Use of corticosteroids in admitted patients§ 98.7 87.5 100 100 99 94.9 84.4 100
Length of prescription of corticosteroids|| 53.6 73.2 93.9 56.4 79 77.8 63.7 68.5
Antibiotics¶ 40.2 47.4 32.7 80.2 35 50.7 52.1 50.3
High-dose inhaled corticosteroids# 6.09 4.3 0 1 3 0 3 8.4
*Percentage of physicians who stated nebulized salbutamol given every 20 minutes as ﬁrst choice for treatment of an acute asthma attack.
**Percentage of physicians who frequently or always administered systemic corticosteroids in an outpatient setting (emergency department/polyclinic) in the treatment of acute
asthma.
‡Percentage of physicians who frequently or always administered inhaled corticosteroids in an outpatient setting (emergency department/polyclinic) in the treatment of acute asthma.
§Percentage of physicians who use corticosteroids in admitted patients.
||Percentage of physicians who give 3 to 5 days of corticosteroids at the same dosage throughout that period for acute asthma.
¶Percentage of physicians who give antibiotics for cases of acute asthma.
#Percentage of physicians who use high-dose inhaled corticosteroids for acute asthma.
TABLE 5. Percentages of Physicians Who Use LABA Monotherapy as a First-Choice Treatment for Asthma Maintenance
in the Speciﬁed Age Groups
India Australia Sri Lanka Taiwan China* Indonesia Singapore Philippines
Infants 9.8 1.4 4.1 6.9 60 76.3 8.1 7.7
Preschoolers 15.9 1.8 10.2 8.9 58 43.3 8.7 7.7
Older children 3.8 2.2 6.1 5.9 59 28.8 5.8 0
*Results for this country may include physicians who may use LABA as both monotherapy and add-on.
TABLE 6. Percentages of Physicians Who Use Inhaled Corticosteroids as a First-Choice Treatment for Asthma
Maintenance in the Speciﬁed Age Groups
India Australia Sri Lanka Taiwan China Indonesia Singapore Philippines
Infants 52.4 34.5 81.6 58.0 85.0 11.0 36.4 30.8
Preschoolers 48.7 38.8 69.4 41.1 83.0 10.0 46.2 35.0
Older children 42.6 40.4 69.4 59.8 81.0 24.0 42.2 35.0
TABLE 7. Percentages of Physicians Who Use Montelukast as a First-Choice Treatment for Asthma Maintenance
in the Speciﬁed Age Groups
India Australia Sri Lanka Taiwan China Indonesia Singapore Philippines
Infants 8.5 14.5 0.0 42.4 72.0 1.9 12.7 0.0
Preschoolers 10.9 22.5 2.0 45.3 74.0 1.9 11.0 7.7
Older children 0.0 9.2 0.0 19.8 72.0 1.4 8.1 15.4
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imperative that some audit must be done on the management
of these patients to ensure more cost-effective management
especially because it has long been accepted that evidence-
based clinical guidelines for the treatment of asthma (such as
GINA guidelines) and asthma education are the best methods
available to allow patients to receive a high quality of care and
better disease outcomes.10Y12 Although some studies show
that the asthma burden may be plateauing,13Y15 this is hy-
pothesized to be caused by an improvement in intervention
and prevention efforts. This emphasizes the importance of
proper management of asthma to reduce the health care burden
of this disease.
With regard to the response rate, the signiﬁcantly higher
response rates in the Philippines and Indonesia were probably
because most of the questionnaires were distributed personally
to the respondents as compared with the other countries, where
the questionnaires were distributed mainly by post. In ad-
dition, it must be emphasized that the low response rate for
many of the countries may affect the interpretation of the
results. Physicians who completed the questionnaire would be
assumed to have a greater interest in the management of
asthma than the nonresponder group, and thus would probably
be more knowledgeable in management of such patients.
Thus, the results may reﬂect an overestimation of the know-
ledge on this subject of the general population of physicians
in Southeast Asia, thus making it safe to conclude that asth-
ma is treated even less optimally than is reﬂected in the re-
sults of this study. In addition, as this study was conducted
mostly in urban regions, the results may not reﬂect the prac-
tices in the vast rural areas of many of the studied countries.
There is a possibility that asthma is treated even more poorly
in these areas, as development of programs and resources
are limited.16
Score cards or diaries, peak ﬂow meters and spirometry
are used by only a small percentage of physicians to monitor
asthma. Except spirometry, the others are relatively inexpen-
sive and convenient methods to monitor asthma. The reasons
for these methods being unpopular may be a lack of aware-
ness among physicians about these methods and/or tech-
niques of use, or even perhaps unfamiliarity with the use of
these methods to titrate the step-care management of asthma
to the child’s current level of control. It is suggested that
standard scoring systems be implemented for each country,
and simple diaries be available in all clinics and hospitals to
be given out to all children with asthma seeking treatment.
Children should record their symptoms in the diaries and bring
them for every follow-up visit thereafter. Cheaply priced peak
ﬂow meters should be made available to all practitioners, and
perhaps even the patients, so that they may be able to monitor
their asthma at home.
The administration of systemic and inhaled cortico-
steroids in an outpatient setting in the treatment of acute asth-
ma is not favored by some physicians. It has been shown that
systemic glucocorticosteroids speed resolution of exacerba-
tions17,18 and that the combination of high-dose inhaled glu-
cocorticosteroids and salbutamol in acute asthma provides
greater bronchodilation than salbutamol alone.19 The underuse
of steroids by physicians in Asia to treat acute asthma has been
observed before.20 Perhaps the use of corticosteroids, whether
systemic or inhaled, is not favored by some physicians because
of the common misconception that steroids are harmful to
young children, particularly with regard to growth, although
this theory has long been debunked.21
A good number of respondents were knowledgeable
about the appropriate length of duration for prescription of
oral corticosteroids, which was 3 to 5 days, without the need
FIGURE 1. The GDP per head versus choice of monotherapy in preschoolers (China data may include use as both monotherapy and
polytherapy).
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for tailing down of the dose. Regarding use of antibiotics, in-
appropriate use in acute exacerbations is still present. In
western countries, inappropriate antibiotic use is declining,
and this is attributed to education of the physicians on ap-
propriate antibiotic use.22,23 More extensive education of
practitioners must be done in the Asia-Paciﬁc to improve
this statistic.
For maintenance treatment, it is of concern that many
Asian physicians’ ﬁrst choice of therapy in infants and pre-
schoolers is LABA monotherapy. Global Initiative for Asthma
guidelines state that LABA should not be used in children
5 years or younger because the safety proﬁle of the drug in
that age group has not been sufﬁciently studied. The LABAs
in children older than 5 years should only be used as an add-
on therapy for patients whose asthma is insufﬁciently con-
trolled by medium doses of inhaled glucocorticosteroids or as
single-dose therapy before vigorous exercise and not as mo-
notherapy.24 In fact, there have been studies that show that
LABAs may increase the risk of asthma deaths because of
the masking of symptoms.25 It can only be speculated
why LABAs have become so popular with physicians,
especially in Indonesia, as our data show. Perhaps nonquan-
tiﬁable factors such as marketing and local practice pat-
terns are at work. We did not analyze the other combinations
that physicians indicated as ﬁrst choice in which LABAs are
used with other drugs (such as inhaled corticosteroids). Hence,
the statistics of physicians using LABAs at all to treat child-
ren younger than 5 years are, in fact, much higher than this
study shows.
Inhaled corticosteroids, thankfully, are generally the
more popular choice in terms of maintenance therapy for pe-
diatric patients with asthma, with the exception of Indonesia,
where the use of LABAs clearly outweigh the use of corti-
costeroids. It must be reiterated that Global Initiative for
Asthma guidelines highly recommend the use of inhaled cor-
ticosteroids as maintenance therapy in children even younger
than 5 years. It describes inhaled corticosteroids as being the
Bmost effective controller medications currently available.[
Of note, montelukast is gaining popularity in Southeast
Asia. Montelukast has been studied and shown to be an efﬁ-
cacious therapy for asthma in children aged 2 to 14 years and
is generally well tolerated without clinically important adverse
effects.26,27 However, its cost is still relatively high compared
with the other forms of therapy, which would greatly inﬂuence
its prescription because a large percentage of patients would
not be able to afford it long-term.
Certainly, affordability may play a part in the choice
of management. A general comparison of choice of therapy
in preschoolers versus gross domestic product (GDP) per
head28 demonstrates that more expensive therapy such as
montelukast is higher in more afﬂuent nations, whereas
cheaper LABA monotherapy is more commonly practiced in
areas of lower GDP (Fig. 1). Once again, medication pricing
and marketing practices are confounders that are not easily
ruled out statistically and may very well inﬂuence these
results. It is encouraging to note the high use of inhaled
steroids in most countries regardless of overall afﬂuence.
In conclusion, it must be emphasized that the standard
of asthma care in children is likely to be poorer than what this
study shows, as mostly urban regions were surveyed. More-
over, the response rate has room for improvement, with
responder bias possibly altering the results. Several areas have
been identiﬁed as having room for improvement, including
better monitoring of childhood asthma, and most importantly,
less use of LABA monotherapy, especially in young children
with asthma.
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